These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 16084533)

  • 1. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background.
    Kalousová M; Zima T; Tesar V; Dusilová-Sulková S; Skrha J
    Mutat Res; 2005 Nov; 579(1-2):37-46. PubMed ID: 16084533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.
    Kalousová M; Jáchymová M; Germanová A; Kubena AA; Tesar V; Zima T
    Kidney Blood Press Res; 2010; 33(1):30-6. PubMed ID: 20185929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
    Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
    Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products in clinical nephrology.
    Kalousová M; Zima T; Tesar V; Stípek S; Sulková S
    Kidney Blood Press Res; 2004; 27(1):18-28. PubMed ID: 14679311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
    Ramasamy R; Yan SF; Schmidt AM
    Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does renal function influence plasma levels of advanced glycation and oxidation protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis?
    Rysavá R; Kalousová M; Zima T; Dostál C; Merta M; Tesar V
    Kidney Blood Press Res; 2007; 30(1):1-7. PubMed ID: 17191033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
    Nishizawa Y; Koyama H
    J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variability in the RAGE gene: possible implications for nutrigenetics, nutrigenomics, and understanding the susceptibility to diabetic complications.
    Kanková K; Sebeková K
    Mol Nutr Food Res; 2005 Jul; 49(7):700-9. PubMed ID: 15937999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
    Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
    Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
    Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
    Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K; Watson A; Soro-Paavonen A
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD.
    Wu L; Ma L; Nicholson LF; Black PN
    Respir Med; 2011 Mar; 105(3):329-36. PubMed ID: 21112201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma advanced glycation end products are decreased in obese children compared with lean controls.
    Sebeková K; Somoza V; Jarcusková M; Heidland A; Podracká L
    Int J Pediatr Obes; 2009; 4(2):112-8. PubMed ID: 18645732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells.
    Chen J; Huang L; Song M; Yu S; Gao P; Jing J
    J Cardiovasc Pharmacol; 2009 May; 53(5):359-67. PubMed ID: 19276989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
    Kanková K
    Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer.
    Krechler T; Jáchymová M; Mestek O; Zák A; Zima T; Kalousová M
    Clin Biochem; 2010 Jul; 43(10-11):882-6. PubMed ID: 20398646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.
    Yan SF; Ramasamy R; Naka Y; Schmidt AM
    Circ Res; 2003 Dec; 93(12):1159-69. PubMed ID: 14670831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of advanced glycation end products and their receptors in development of diabetic neuropathy.
    Wada R; Yagihashi S
    Ann N Y Acad Sci; 2005 Jun; 1043():598-604. PubMed ID: 16037282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.